-
Teclistamab, sold
under the
brand name Tecvayli, is a
human bispecific monoclonal antibody used for the
treatment of
relapsed and
refractory multiple...
- (talquetamab) for the
treatment of relapsed/refractory MM (Janssen)
Tecvayli (
teclistamab) for the
treatment of relapsed/refractory MM (Janssen)
Tepezza (teprotumumab)...
- hdl:10665/330896. "Janssen
Marks First Approval Worldwide for
Tecvayli (
teclistamab) with EC
Authorisation of First-in-class
Bispecific Antibody for the...
- antibodies. The
first drug in this
class approved for
multiple myeloma is
Teclistamab, but
again its use is
presently reserved for
patients in
later stages...
-
Clinical trial number NCT04722146 for "A Multi-arm
Phase 1b
Study of
Teclistamab With
Other Anticancer Therapies in Parti****nts With
Multiple Myeloma"...
-
Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumabâ€
Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab...
-
intrahepatic cholangiocarcinoma with FGFR2 gene
fusions or
other rearrangements Teclistamab Janssen multiple myeloma Teplizumab Provention Bio
delay the
onset of...
-
Naxitamab L01FX22
Loncastuximab tesirine L01FX23
Tisotumab vedotin L01FX24
Teclistamab L01FX25
Mosunetuzumab L01FX26
Mirvetuximab soravtansine L01FX27 Epcoritamab...
-
Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumabâ€
Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab...
- FDA: blinatumomab, emacizumab, amivantamab, tebentafusp, faricimab,
teclistamab, mosunetuzumab, epcoritamab, glofitamab.
Among the bsAb
programs currently...
